On May 17, 2018 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois, from June 1-5, 2018 (Press release, Seattle Genetics, MAY 17, 2018, View Source;p=RssLanding&cat=news&id=2349592 [SID1234526775]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The abstracts being presented at ASCO (Free ASCO Whitepaper) 2018 highlight the depth of our clinical program in multiple solid tumors and hematological malignancies," said Robert Lechleider, M.D., Senior Vice President, Clinical Development at Seattle Genetics. "Of note, an oral presentation will feature updated data from a phase 1 study of enfortumab vedotin for patients with metastatic urothelial cancer. Data from this study formed the basis of the recent FDA Breakthrough Therapy Designation for enfortumab vedotin. In addition, multiple posters featuring sub-analyses from the ECHELON-1 trial of ADCETRIS provide continued strong rationale for ADCETRIS combination use in the treatment of patients with frontline Stage 3 and 4 classical Hodgkin lymphoma."
The abstracts published in advance of the ASCO (Free ASCO Whitepaper) meeting were made available yesterday on the ASCO (Free ASCO Whitepaper) website at www.asco.org.
Urothelial Cancer
(Abstract #4504) "Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)"
Presenter: J. Rosenberg, M.D., Memorial Sloan Kettering Cancer Center
Oral Abstract Session: Genitourinary (Nonprostate) Cancer
Date and Time: Sunday, June 3, 9:12 a.m.-9:24 a.m. CDT (session begins at 8:00 a.m.)
Location: Arie Crown Theater
(Abstract #TPS4590) "EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy"
Presenter: J. Rosenberg, M.D., Memorial Sloan Kettering Cancer Center
Poster Session: Genitourinary (Nonprostate) Cancer
Date and Time: Saturday, June 2, 8:00 a.m.-11:30 a.m. CDT
Location: Hall A, Poster Board #414a
Hodgkin Lymphoma
(Abstract #7534) "Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma"
Presenter: D. Straus, M.D., Memorial Sloan Kettering Cancer Center
Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT
Location: Hall A, Poster Board #171
(Abstract #7541) "Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results"
Presenter: R. Ramchandren, M.D., Barbara Ann Karmanos Cancer Institute
Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT
Location: Hall A, Poster Board #178
(Abstract #7542) "Long-term follow-up of brentuximab vedotin +/- dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma"
Presenter: J. Friedburg, M.D., University of Rochester Medical Center
Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT
Location: Hall A, Poster Board #179
(Abstract #7539) "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS)"
Presenter: R. Chen, M.D., Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT
Location: Hall A, Poster Board #176
Breast Cancer
(Abstract #1015) "Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer"
Presenter: R. Murthy, M.D., University of Texas MD Anderson Cancer Center
Poster Session: Breast Cancer – Metastatic
Date and Time: Saturday, June 2, 8:00 a.m.-11:30 a.m. CDT
Location: Hall A, Poster Board #96
Discussed at Poster Discussion at Hall D1 on Saturday, June 2, 1:15 p.m.-2:30 p.m. CDT
Cervical Cancer
(Abstract #TPS5601) "A single-arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer"
Presenter: R. Coleman, M.D., The University of Texas MD Anderson Cancer Center
Poster Session: Gynecologic Cancer
Date and Time: Monday, June 4, 1:15 p.m.-4:45 p.m. CDT
Location: Hall A, Poster Board #327b
Additional Cancers
(Abstract #3093) "SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors"
Presenter: J. Grilley-Olson, M.D., UNC Lineberger Comprehensive Cancer Center/University of North Carolina Chapel Hill
Poster Session: Developmental Therapeutics – Immunotherapy
Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT
Location: Hall A, Poster Board #307